Table 1 Ordinary least square (OLS) regression results with main terms used in the model and p-values for individual methylation changes one year after the start of CBCT compared to prior to CBCT.

From: Changes in methylation associated with development of metabolic syndrome in testicular cancer patients treated with cisplatin chemotherapy

 

Intercept

MetS + prior to CBCT

MetS + developed within 5 years

Age

PtAUC

Leucocyte change

Δ LINE-1

1.97

p = 0.312

1.57

p = 0.032*

1.89

p = 0.017*

-0.076

p = 0.080

1.6*10− 10

p = 0.994

0.24

p = 0.186

Δ AC090023

-6.33

p = 0.101

-6.29

p = 0.001**

-2.37

p = 0.123

0.10

p = 0.223

-5.7*102

p = 0.195

0.37

p = 0.277

Δ CACNA1D

4.38

p = 0.460

-4.04

p = 0.061

1.10

p = 0.468

0.020

p = 0.875

-1.00*101

p = 0.110

1.64

p = 0.004**

Δ NCAM2

11.17

p = 0.084

-5.75

p = 0.014*

-1.32

p = 0.604

-0.21

p = 0.141

-9.8*102

p = 0.184

0.98

p = 0.095

Δ TOM1L2

1.35

p = 0.602

-3.39

p = 0.001**

-1.41

p = 0.176

-0.002

p = 0.974

-4.69*102

p = 0.120

0.32

p = 0.174

  1. MetS = Metabolic syndrome; PtAUC = Platinum exposure. Significance p ≤ 0.05 is marked with bold text and *, significance p ≤ 0.005 is marked with bold text and **.
Back to article page